LifeStance Health Group (LFST) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of LifeStance Health Group (NASDAQ: LFST) in the last few weeks:

• 11/13/2025 – LifeStance Health Group had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – LifeStance Health Group is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $8.00 price target on the stock.
• 11/7/2025 – LifeStance Health Group had its price target raised by analysts at UBS Group AG from $9.00 to $10.00. They now have a “buy” rating on the stock.
• 11/6/2025 – LifeStance Health Group had its price target raised by analysts at BTIG Research from $8.00 to $9.00. They now have a “buy” rating on the stock.
• 11/5/2025 – LifeStance Health Group was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 10/11/2025 – LifeStance Health Group was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/8/2025 – LifeStance Health Group had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – LifeStance Health Group was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 9/27/2025 – LifeStance Health Group had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.